Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these results and what they could mean for investors.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are planned.

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce competition in the weight-loss market.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.